BERLIN, Oct. 9, 2007 (PRIME NEWSWIRE) -- Jerini AG (Frankfurt:JI4) announced today that its wholly-owned subsidiary, Jerini Ophthalmic, Inc., has treated the first patient in its Phase I clinical trial evaluating JSM 6427 for the treatment of age-related macular degeneration (AMD). JSM 6427 is a small molecule in development to prevent the progression of dry AMD to wet AMD, an unmet medical need affecting 600,000 patients in the United States. The Phase I trial will assess the safety of JSM 6427 in patients suffering from AMD and treat up to 36 patients with either single or repeat intravitreal doses.
